MA28108A1 - Utilisation de composes organiques - Google Patents

Utilisation de composes organiques

Info

Publication number
MA28108A1
MA28108A1 MA28962A MA28962A MA28108A1 MA 28108 A1 MA28108 A1 MA 28108A1 MA 28962 A MA28962 A MA 28962A MA 28962 A MA28962 A MA 28962A MA 28108 A1 MA28108 A1 MA 28108A1
Authority
MA
Morocco
Prior art keywords
organic compounds
benazepril
mortality
administering
combination
Prior art date
Application number
MA28962A
Other languages
English (en)
Inventor
Ken Jamerson
Nab Malcolm Mac
Bertram Pitt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28108A1 publication Critical patent/MA28108A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

L'invention concerne un procédé pour réduire la morbidité et/ou la mortalité cardio-vasculaire, consistant à administrer une combinaison comprenant un inhibiteur de l'ACE et un inhibiteur calcique, en particulier du benazepril et du besylate d'amlodipine.
MA28962A 2003-10-20 2006-04-25 Utilisation de composes organiques MA28108A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51263403P 2003-10-20 2003-10-20

Publications (1)

Publication Number Publication Date
MA28108A1 true MA28108A1 (fr) 2006-08-01

Family

ID=34465367

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28962A MA28108A1 (fr) 2003-10-20 2006-04-25 Utilisation de composes organiques

Country Status (19)

Country Link
US (2) US20060233876A1 (fr)
EP (1) EP1776115A2 (fr)
JP (1) JP2007511473A (fr)
KR (1) KR20060120126A (fr)
CN (1) CN101137367A (fr)
AU (1) AU2004281541B2 (fr)
BR (1) BRPI0415530A (fr)
CA (1) CA2542757A1 (fr)
IL (1) IL174927A0 (fr)
IS (1) IS8470A (fr)
MA (1) MA28108A1 (fr)
MX (1) MXPA06004369A (fr)
NO (1) NO20062236L (fr)
RU (1) RU2006117198A (fr)
SG (1) SG147456A1 (fr)
TN (1) TNSN06111A1 (fr)
TW (1) TW200524591A (fr)
WO (1) WO2005037278A2 (fr)
ZA (1) ZA200602994B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9940405B2 (en) 2011-04-05 2018-04-10 Beyondcore Holdings, Llc Automatically optimizing business process platforms
US10127130B2 (en) * 2005-03-18 2018-11-13 Salesforce.Com Identifying contributors that explain differences between a data set and a subset of the data set
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
CN101985035A (zh) * 2009-07-14 2011-03-16 邬林祥 一种治疗高血压含培哚普利的复方制剂
SI2585051T2 (sl) 2010-06-23 2020-07-31 Krka, D.D., Novo Mesto Farmacevtske oralne odmerne oblike,ki obsegajo lerkanidipin in enalapril in njune farmacevtsko sprejemljive soli
US10796232B2 (en) 2011-12-04 2020-10-06 Salesforce.Com, Inc. Explaining differences between predicted outcomes and actual outcomes of a process
US10802687B2 (en) 2011-12-04 2020-10-13 Salesforce.Com, Inc. Displaying differences between different data sets of a process
CN102440993B (zh) * 2011-12-08 2013-04-17 扬子江药业集团广州海瑞药业有限公司 一种氨氯地平和贝那普利的药物组合物
BR112014014896A2 (pt) 2011-12-21 2017-06-13 Novartis Ag nova combinação
CN102688245A (zh) * 2012-06-11 2012-09-26 北京阜康仁生物制药科技有限公司 一种稳定的氨氯地平与贝那普利药用组合物及其制备方法
JP2014219945A (ja) * 2013-05-10 2014-11-20 富士通株式会社 治験情報出力装置、治験情報出力方法および治験情報出力プログラム
US20200111575A1 (en) * 2018-10-04 2020-04-09 Babylon Partners Limited Producing a multidimensional space data structure to perform survival analysis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
EP0795327A1 (fr) * 1996-03-13 1997-09-17 Pfizer Inc. Utilisation de l'amlodipine pour le traitement et la prophylaxie de l'insuffisance cardiaque congestive d'origine non-ischémique
JP2004516266A (ja) * 2000-12-18 2004-06-03 ノバルティス アクチエンゲゼルシャフト アムロジピンおよびベナゼブリルの治療的組み合わせ
PE20040468A1 (es) * 2002-05-17 2004-09-14 Novartis Ag Combinacion de compuestos organicos

Also Published As

Publication number Publication date
US20060233876A1 (en) 2006-10-19
NO20062236L (no) 2006-07-19
CN101137367A (zh) 2008-03-05
JP2007511473A (ja) 2007-05-10
US20080242659A1 (en) 2008-10-02
SG147456A1 (en) 2008-11-28
AU2004281541B2 (en) 2008-05-01
BRPI0415530A (pt) 2006-12-26
ZA200602994B (en) 2008-03-26
TNSN06111A1 (en) 2007-11-15
IL174927A0 (en) 2008-04-13
CA2542757A1 (fr) 2005-04-28
TW200524591A (en) 2005-08-01
WO2005037278A2 (fr) 2005-04-28
MXPA06004369A (es) 2006-06-14
EP1776115A2 (fr) 2007-04-25
IS8470A (is) 2006-05-16
KR20060120126A (ko) 2006-11-24
RU2006117198A (ru) 2007-12-10
WO2005037278A3 (fr) 2007-05-10
AU2004281541A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
MA28108A1 (fr) Utilisation de composes organiques
DK1663206T3 (da) 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imizadol-2-thion som ikke-sedativ alpha 2A-agonist
WO1999048523A3 (fr) Antagonistes de mediateurs inflammatoires
NO20021450D0 (no) Cykliske aminforbindelser som CCR5 antagonister
EA200300580A1 (ru) Соединения лактама
LV12639B (lv) Bifenilsulfonamidi ka duali angiotenzina un endotelina receptoru antagonisti
EA200200940A1 (ru) Производные азетидина, способ их получения и содержащие их фармацевтические композиции
AU2426602A (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
EA200501075A1 (ru) Лекарственное средство для профилактики и лечения артериосклероза и гипертензии
DE69903333D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
MA28269A1 (fr) Arylpyrazoles substitués servant d'agents parasiticides
YU39803A (sh) Jedinjenja piperazinilpirazina kao agonisti ili antagonisti serotonin 5ht-2-receptora
MA30889B1 (fr) Inhibiteurs de la kinase mapk/erk
DE69908173D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
EA200001039A1 (ru) Кальцилитические соединения
EA200401455A1 (ru) Производные бензоксазина в качестве модуляторов 5-htи их применение
WO2004112704A3 (fr) Composes de piperidine substitues et procedes d'utilisation associes
BR0302680A (pt) Dispositivo oftálmico contendo compostos heterocìclicos e métodos para produção dos mesmos
EP1657293A3 (fr) Compositions lubrifiantes comprenant une diarylamine
WO2005042021A3 (fr) Composition pharmaceutique contenant un agoniste des recepteurs beta-3-adrenergiques et un antagoniste alpha et/ou un inhibiteur de la 5-alpha-reductase
WO2004048930A3 (fr) METHODE PERMETTANT DE CONTRER UN CHANGEMENT PATHOLOGIQUE DANS LA VOIE ss-ADRENERGIQUE
NO20035148D0 (no) Tri- og tetra-aza-acenaftylenderivater som CRF- reseptorantagonister
EP1553040A4 (fr) Machinerie d'ascenseur
WO2001070684A3 (fr) Ligands peptidomimetiques pour recepteurs cellulaires et canaux ioniques